Arcutis Biotherapeutics, Inc. ARQT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $105.4M+60.1% | $129.5M+81.5% | $99.22M+122% | $81.5M+164% | $65.85M+32.8% | ||
| $9.78M+10.8% | $11.69M+69.3% | $8.69M+57.8% | $7.49M+116% | $8.83M+171% | ||
| $95.61M+67.7% | $117.82M+82.8% | $90.53M+131% | $74.01M+170% | $57.02M+23.1% | ||
| 90.7%+4.1pp | 91%+0.7pp | 91.2%+3.5pp | 90.8%+2.0pp | 86.6%-6.8pp | ||
| $30.63M+74.6% | $20.45M+41.2% | $19.6M+0.5% | $19.45M+0.8% | $17.54M-24.2% | ||
| $74.08M+15.7% | $78.98M+37.1% | $62.4M+6.1% | $69.17M+18.9% | $64M+16.8% | ||
| $114.49M+26.7% | $111.12M+40.7% | $90.69M+8.2% | $96.12M+18.8% | $90.38M+11.3% | ||
| -$9.09M+62.9% | —— | $8.53M+122% | -$14.61M+70.8% | -$24.53M+22.4% | ||
| -8.6%+28.6pp | —— | 8.6%+95.9pp | -17.9%+144pp | -37.3%+26.5pp | ||
| $4.37M+46.5% | $3M-45.9% | $3.07M-53.8% | $3.03M-59.5% | $2.98M-60.1% | ||
| -$20K-110% | —— | $2.04M-51.3% | $2.1M-59.9% | $193K-95.2% | ||
| $93K-66.7% | $470K+45.5% | $80K— | $342K— | $279K-13.9% | ||
| -$11.3M+54.9% | —— | $7.41M+118% | -$15.89M+69.6% | -$25.06M+29.2% | ||
| -10.7%+27.3pp | —— | 7.5%+100pp | -19.5%+150pp | -38.1%+33.3pp | ||
| -$0.09+55.0% | —— | $0.06+118% | -$0.13+69.0% | -$0.20+37.5% | ||
| -$8.53M+60.1% | —— | $9.09M+124% | -$14.05M+71.7% | -$21.4M+31.6% | ||
| -8.1%+24.4pp | —— | 9.2%+93.2pp | -17.2%+144pp | -32.5%+30.6pp | ||
| -$9.09M+62.9% | —— | $8.53M+122% | -$14.61M+70.8% | -$24.53M+22.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s revenue?
- Arcutis Biotherapeutics, Inc. (ARQT) generated $415.6M in revenue over the trailing twelve months, up 95.3% year over year.
- Is Arcutis Biotherapeutics, Inc. profitable?
- Arcutis Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $44.8M over the trailing twelve months, a -13.9% net margin.
- What are Arcutis Biotherapeutics, Inc.'s profit margins?
- Gross margin is 90.9% and operating margin is -12.0%, with a -13.9% net margin.
- What is Arcutis Biotherapeutics, Inc.'s earnings per share?
- Arcutis Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.36.
- Where does Arcutis Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
